Paclitaxel oral dosage form soon available.

Published: 2000-09-25 11:52:00

Updated: 2000-09-25 11:52:00

Hanmi Pharmaceutical company announced on Sept. 19 that an oral dosage form of Paclitaxel, an excellent anticancer agent, had been successfully developed for the first time over the world under a close research cooperation with Korea Chemical Research Institute. Hanmi earlier in 1996 developed it...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK